Actinogen Medical (ASX:ACW) has released topline results from its pivotal, placebo-controlled XanaMIA trial of oral emestedastat (Xanamem®) in 247 patients with mild to moderate Alzheimer's disease over 36 weeks of treatment, disclosing that Xanamem was numerically but not statistically superior to placebo on the primary endpoint of delayed disease progression as measured by the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB).

Key Points

  • Xanamem was numerically but not statistically superior to placebo for the primary CDR-SB endpoint at Week 36, with a mean benefit of 0.10 CDR-SB points (p=0.65)
  • A statistically significant benefit on the CDR-SB zero progression rate (40% vs. 22%, p=0.02) was observed in participants above the median age of 75 years, alongside a clinically significant 30% disease slowing
  • No serious adverse events were attributed to Xanamem over the 36-week treatment period
  • The Open Label Extension phase showed no mean progression in the first 29 participants at 24 weeks, with the next data milestone expected in Q1 CY2027
  • The company held a cash balance of $18.9 million with no debt as of the announcement date, providing a runway into CY2028

XanaMIA Primary Endpoint and Older Patient Subgroup Findings

In the overall population of 247 patients, Xanamem did not achieve statistical superiority over placebo on the primary endpoint at Weeks 12, 24 and 36, recording a mean CDR-SB benefit of 0.10 points at Week 36 (p=0.65). In a prespecified analysis of participants above the median age of 75 years, a statistically significant benefit on the CDR-SB zero progression rate was observed at 40% versus 22% (p=0.02), together with a clinically significant mean CDR-SB superiority of 0.39 points at Week 36 (p=0.22), representing 30% disease slowing. The company also disclosed that participants above the median age represent more than 70% of patients with Alzheimer's disease.

Safety Profile and Open Label Extension Data

Xanamem 10 mg administered daily demonstrated a favourable safety profile over 36 weeks, replicating results previously established over up to 12 weeks of treatment. No serious adverse events were attributed to Xanamem during the trial period. In the Open Label Extension phase, disease stabilisation over 24 weeks — defined as no mean progression on the CDR-SB — was observed in the first 29 participants to reach that timepoint. The company stated the OLE phase will continue to gather additional data, with the next milestone to be reported when approximately 100 participants have reached at least 24 weeks of treatment, expected in Q1 CY2027.

Cash Position, Cost Measures and New Patent Filing

As of the announcement date, Actinogen Medical held a cash balance of $18.9 million and carried no debt, with a significant accrued R&D tax incentive disclosed given eligible R&D spend in the first half of FY2027. The company stated that cash commitments will drop substantially from early CY2027 as the XanaMIA trial is closed out. Immediate steps disclosed include suspending future Phase 3 expenditure, focusing spending on the OLE trial, and expanding the intellectual property portfolio through a new patent filing covering Xanamem treatment in older, more advanced Alzheimer's disease patients. The company also stated it intends to explore results with potential co-development partners.